SMC backs drug for male urinary symptoms in Scotland
The Scottish Medicines Consortium has approved solifenacin 6mg/tamsulosin 0.4mg (Vesomni) for use in NHS Scotland.
It has been accepted for the treatment of moderate to severe storage symptoms and voiding symptoms associated with benign prostatic hyperplasia (BPH) in men not adequately responding to monotherapy.
Tamsulosin is an alpha-blocker, commonly prescribed to treat lower urinary tract symptoms associated with BPH due to its efficacy in relieving symptoms related to urinary voiding.
Solifenacin is an anti-muscarinic treatment used to treat urge incontinence and increased urinary frequency and urgency.
- Read the full SMC guidance